Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: Possible relation to serotonin 5HT2a receptor blockade

Pharmacopsychiatry

Volumn 33, Issue 1, 2000, Pages 38-41

  Lauterbach, E C ^a,b   Abdelhamid, A ^a   Annandale, J B ^a  

^a MERCER UNIVERSITY   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE; TRAZODONE;

ADULT; ARTICLE; ATAXIA; CASE REPORT; DRUG INDUCED DISEASE; FEMALE; HALLUCINATION; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; URINE RETENTION; VISUAL HALLUCINATION;

EID: 0033964967     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8452     Document Type: Article

References (30)

1. 1 Abraham HD: Visual phenomenology of the LSD flashback. Arch. Gen. Psychiatry 1983; 40: 884-889
2. 2 Abraham HD: Visual hallucinations in macular degeneration. Am. J. Psychiatry 1993; 150: 1758
3. 3 Abraham HD, Mamen A: LSD-like panic from risperidone in post-LSD visual disorder. J. Clin. Psychopharmacol. 1996; 16: 238-241
4. 4 Aghajanian GK: Serotonin and the action of LSD in the brain. Psychiatr. Ann. 1994; 24: 137-141
5. 5 Almaula N, Ebersole BJ, Ballesteros JA, Weinstein H, Sealfon SC: Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytrytamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol. Pharmacol. 1996; 50: 34-42
6. 6 Callahan PM, Cunningham KA: Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). Eur. J. Pharmacol. 1994; 257: 27-38
7. 7 Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci. Lett. 1994; 181: 65-68
8. 8 Geller TJ, Bellur SN: Peduncular hallucinosis: magnetic resonance imaging confirmation of mesencephalic infarction during life. Ann. Neurol. 1987; 21: 602-604
9. 9 Giannangeli G, Cazzolla N, Luparini MR, Magnani M, Mabilia M, Picconi G, Tomaselli M, Baiocchi L: Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity. J. Med. Chem. 1999; 42: 336-345
10. 10 Glennon RA: Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 1990; 3: 509-517
11. 11 Green KL, Grant KA: Evidence for overshadowing by components of the heterogeneous discriminative stimulus effects of ethanol. Drug Alcohol. Depend. 1998; 52: 149-159
12. 12 Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust C: An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol. Bull. 1996; 32: 671-676
13. 13 Hughes MS, Lessell S: Trazodone-induced palinopsia. Arch. Ophthalmol. 1990; 108: 399-400
14. 14 Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, Wichmann J, Van Delft AM: Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur. Neuropsychopharmacol. 1998; 8: 161-168
15. 15 Kawasaki A, Purvin V: Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD). Arch. Ophthalmol. 1996; 114: 47-50
16. 16 Kolmel HW: Peduncular hallucinations. J. Neurol. 1991; 238: 457-459
17. 17 Kraus RP: Visual "trails" with nefazodone treatment. Am. J. Psychiatry 1996; 153: 1365-1366
18. 18 Lauterbach EC, Spears TE: Long-term psychiatric and neurologic treatment after a traumatic midbrain lesion. Neurocase. 1997; 3: 98-103
19. 19 Lima L, Salazar M, Trejo E: Modulation of 5HT1A receptors in the hippocampus and the raphe area of rats treated with clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 663-677
20. 20 Lima L, Trejo E, Urbina M: Serotonin turnover rate, [3H]paroxetine binding sites, and 5-HT1A receptors in the hippocampus of rats subchronically treated with clonazepam. Neuropharmacology 1995; 34: 1327-1333
21. 21 Marek GJ, Aghajanian GK: LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2a receptors on interneurons in rat piriform cortex. J. Pharmacol. Exp. Ther. 1996; 278: 1373-1382
22. 22 Morehead DB: Exacerbation of hallucinogen - persisting perception disorder with risperidone. J. Clin. Psychopharmacol. 1997; 17: 327-328
23. 23 Moser PC, Redfern PH: The effect of benzodiazepines on the 5-HT agonist-induced head-twitch response in mice. Eur. J. Pharmacol 1988; 151: 223-231
24. 24 Newton RA, Phipps SL, Flanigan TP, Newberry NR, Carey JE, Kumar C, McDonald B, Chen C, Elliott JM: Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y; comparative stimulation by hallucinogenic drugs. J. Neurochem. 1996; 67: 2521-2531
25. 25 Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B: 5-HT2 and D2 receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl.) 1993; 110: 265-272
26. 26 Sanders-Bush E, Burris KD, Knoth K: Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J. Pharmacol. Exp. Ther. 1988; 246: 924-928
27. 27 Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 1996; 124: 57-73
28. 28 Schwartz K: Nefazodone and visual side effects. Am. J. Psychiatry 1997; 154: 1038
29. 29 Takeuchi H, Yatsugi S, Hatanaka K, Nakato K, Hattori H, Sonoda R, Koshiya K, Fujii M, Yamaguchi T: Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity. Eur. J. Pharmacol. 1997; 329: 27-35
30. 30 Wagner HR, Reches A, Yablonskaya E, Fahn S: Clonazepam-induced up-regulation of serotonin1 and serotonin2 binding sites in rat frontal cortex. Adv. Neurol. 1986; 43: 645-651